Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem®(sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos™ (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in certain countries outside the U.S.
Jazz Pharmaceuticals, Wing B, Spires House, John Smith Drive, Oxford OX4 2RW OXON
At Janssen, helping patients overcome the challenges they face is our mission and privilege. We focus our efforts on discovering first of a kind medicines for cancers where there are limited treatment options and strive to make cancer a manageable, even curable condition.
Janssen Pharmaceutica NV
Tel. +32 (0)14 60 21 11
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Route de Perreux 1
CH – 2017, Boudry
Tel. 032 729 85 00
MolMed S.p.A. is an Italian biotechnology cell & gene company, focused on research, development, manufacturing and clinical validation of innovative anticancer therapies.
MolMed built an original dual business model, including R&D on proprietary onco and onco-hematology products, and third parties GMP development and manufacturing services.
In both areas MolMed delivered outstanding results, owning one of the first authorized cellular therapies (Zalmoxis®, first patient-specific cell therapy, devoted to the treatment of adult patients affected by leukaemia or other high-risk haematological malignancies) authorized by EMA for all EU Countries, as well as a recognized GMP capability, with the first facility authorized in Europe for commercial ex-vivo cell & gene products (Strimvelis and Zalmoxis) manufacturing, serving relevant International partners, such as GSK, Cellectis, Rocket Pharma, Orchard Therapeutics and others.
Founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, one of the leading private scientific research institutes in Italy, MolMed is listed on the (MTA) Milan stock exchange.
Via Olgettina, 58
20132 Milano, Italy
Tel.+39 02 21277.1
Fax. +39 02 21277.325
Abbvie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use tis expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments please visit www.abbvie.com. Follow @abbvie Twitter or view careers on our Facebook or LinkedIn page.
10, rue d’Arcueil
The Association for Training, Education and Research in Hematology, Immunology and Transplantation (ATERHIT) is a non-for profit scientific organization based in Paris (France).
ATERHIT aims to promote clinical, translational and basis research in the fields of hematology, immunology and stem cell transplantation through direct or indirect support to research projects. It also organizes a broad portfolio of educational activities with the goal to disseminate knowledge in its fields of interest and enhance collaborations among all stakeholders. ATERHIT provides support for students, fellows, junior doctors, nurses, and other healthcare professionals who wish to train or gain more experience in this field. The organization can distribute prizes to acknowledge some major achievements in these fields.
Association ATERHIT (Association for Training, Education and Research in Hematology, Immunologie and Transplantation
Hôpital Saint Antoine – Service d’Hématologie Clinique et de Thérapie Cellulaire
184 rue du Faubourg Saint Antoine
Tel. 06.59.66.34.07 (or 02.40.09.72.26)
Clinigen (Clinigen Group) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines to improve the quality of people’s lives around the world.
We are the global leading experts, trusted by both pharmaceutical and biotech companies and healthcare professionals, in providing access to medicines throughout the lifecycle of a medicine; clinical trials, unlicensed and commercial supply.
Clinigen’s mission is to deliver the right medicine to the right patient at the right time operating in three areas of global medicine supply: clinical trials, unlicensed and licensed medicines.
Clinigen Group Plc
Tel. +44 (0) 1283 495 010
H.A.C. Pharma is a French independent pharmaceutical company created in 2007.
H.A.C. Pharma wish to be recognized as an hospital partner by providing therapeutic treatment solutions suited with patient’s needs and healthcare professional’s expectations.
H.A.C PHARMA is focused on the therapeutic areas of gastroenterology, gynecology, severe gestational hypertension, endocrinology, rheumatology, cancer treatment, pediatric neurology.
For more information visit www.hacpharma.com
8 avenue de la Côte de Nacre, Péricentre IV, CS 15236
14052 Caen cedex 4
Tél. 02 31 47 92 46
Fax.02 31 47 92 75
Contact: M. Pascal SERY, Directeur des Opérations France
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on people living with cancer. Our growing pipeline of biologics, small molecules, and immunotherapies is focused on identifying and translating the best scientific breakthroughs into clinical application for patients across a diverse array of solid tumors and hematologic cancers. Today, we have 10 approved oncology medicines and 14 assets currently in clinical development. By maximizing our internal scientific resources and collaborating with other companies, government and academic institutions, as well as patients and non-profit and professional organizations, we are bringing together the brightest and most enterprising minds to take on the toughest cancers. Together we can accelerate breakthrough treatments to patients around the world and work to redefine life with cancer.
Race Oncology is a specialty pharmaceutical company pursuing oncology drugs that have been overlooked by big pharma. Race ow a chemotherapy agent called Bisantrene, which was the subject of more than 40 phase II studies, before it was lost in a series of big pharma mergers during the 1990s. Race intends to complete final clinical development and seek regulatory approval in the US for Acute Myeloid Leukemia (AML), where the drug has orphan drug designation.
L2, 710 Collins St, Melbourne, VIC 3008, Australia
Tel. +61 (0)3 9097-1656
Sanofi Genzyme is part of Sanofi dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Genzyme Europe B.V.
1411 DD NAARDEN
TEL.: +31 (0) 35 699 1200
FAX: +31 (0)35 694 3214
Scientific Education Support (SES)
Steered by world leaders in Hematology, the Hubs provide the latest treatment options, medical information, case studies, recommendations, and expert opinions. The Hubs support community hem-oncologists in making informed treatment decisions and ensuring patients have access to the latest therapies available.
Our mission is to provide up to-date, practical, clinical advice to academic researchers and treating clinicians to improve the lives of patients.
3 AC Court,
Tel. +44 (0) 1372 472 143
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
15 Lyon Rd
Tel. +44 20 8715 1812
Fax. +44 20 8715 1722